DIRS.INFO The most relevant business & tech news

☆ There's a new entry into the weight loss drug boom. Here's the outlook for the stock
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

AstraZeneca is the latest player to enter the weight loss drug arena, a market which some analysts have forecasted could reach $100 billion by 2030 . The GLP-1 drug market is currently dominated by two players: Novo Nordisk , which sells Type 2 diabetes treatment Ozempic and weight loss medication Wegovy, and Eli Lilly , which sells Mounjaro as a treatment for Type 2 diabetes. Lilly just had the weight loss version of its drug, Zepbound , approved by the Food and Drug Administration. It's still early days for AstraZeneca's ECC5004 drug, which is being assessed in a U.S.-based phase 1 trial involving patients with Type 2 diabetes. He currently rates AstraZeneca stock as overweight.

Persons: Eccogene, Wegovy, Eli Lilly, Lilly, It's, Colin White, James Gordon, Morgan Stanley, Mark Purcell, AstraZeneca's Farxiga, Purcell, Michael Bloom, Christina Cheddar, Berk Organizations: AstraZeneca, Novo Nordisk, Food and Drug Administration, Centers for Disease Control, UBS, Wall Street, JPMorgan Locations: U.S

☆ The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it's a top pick
▼ + stars: | 2023-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

Sequence gives subscribers access to GLP-1 medications such as Novo Nordisk's Wegovy and Ozempic. Schenk said the concern about the drop in WW's average revenue per user "seems overblown" and has created a buying opportunity for the stock. Stabilizing core business WW has been focused on stabilizing its core weight loss business. Both developments are a positive for WW's Sequence business. Schenk estimates that around 6 million current or lapsed WW subscribers would qualify for treatment with obesity medication.

Persons: Sima Sistani, Morgan Stanley, Lauren Schenk, Eli Lilly, Schenk, Lilly, Novo Organizations: International, Nordisk's Wegovy, FDA, 3Q, and Drug Administration, Novo Nordisk Locations: Friday's, Novo

The sanctions imposed by Treasury Department's Office of Foreign Assets Control target third-party firms and people alleged to assist Moscow in procuring equipment needed on the battlefield, including suppliers and shippers. In addition, the State Department imposed diplomatic sanctions targeting Russian energy production and its metals and mining sector. Thursday's sanctions targets include Turkish national Berk Turken and his firms, which are alleged to have ties to Russian intelligence. The latest sanctions build on the thousands of financial penalties imposed on Russian infrastructure and its officials, banks and oligarchs. He accused the U.S. and its allies of ignoring Russia’s demand to prevent Ukraine from joining NATO and offer Moscow security guarantees.

Persons: Berk Turken, Janet Yellen, Russia “, ”, SWIFT, Vladimir Putin Organizations: WASHINGTON, United Arab, Treasury Department's, Foreign, State Department, Treasury Department, United Arab Emirates, Financial Engineering, VTB Bank, Central Bank, NATO Locations: United States, Turkey, China, United Arab Emirates, Ukraine, Turkish, Russian, Russia, UAE, ARX, U.S, Moscow

☆ Asteroid that doomed the dinosaurs halted key process for life on Earth, scientists say
▼ + stars: | 2023-10-30 | by ( Katie Hunt | ) edition.cnn.com time to read: +5 min

This dust blocked the sun to an extent that plants were unable to photosynthesize, a biological process critical for life, for almost two years afterward. Pim KaskesAn unexpected killing mechanismTo reach their findings, scientists developed a new computer model to simulate the global climate after the asteroid strike. Fossilized fish found at the site have revealed that the asteroid struck off Mexico’s Yucatán Peninsula in springtime. The team determined that this fine dust could have remained in the atmosphere for up to 15 years after the asteroid strike. The researchers suggested the global climate may have cooled by as much as 15 degrees Celsius.

Persons: ”, Cem Berk Senel, Pim Kaskes, ” Senel, Alfio Alessandro Chiarenza, Chiarenza Organizations: CNN, Royal Observatory of, …, University of Vigo Locations: Mexico, Royal Observatory of Belgium, “, North Dakota, Spain

☆ Dinosaur-killing asteroid impact fouled Earth's atmosphere with dust
▼ + stars: | 2023-10-30 | by ( Will Dunham | ) www.reuters.com time to read: +5 min

The total amount of dust, they calculated, was about 2,000 gigatonnes - exceeding 11 times the weight of Mt. While prior research highlighted two other factors - sulfur released after the impact and soot from the wildfires - this study indicated dust played a larger role than previously known. "It was cold and dark for years," Vrije Universiteit Brussel planetary scientist and study co-author Philippe Claeys said. "While the sulfur stayed about eight to nine years, soot and silicate dust resided in the atmosphere for about 15 years after the impact. "Without the impact, my guess is that mammals - including us - had little chance to become the dominant organisms on this planet."

Persons: grâce, Cem Berk Senel, Philippe Claeys, Özgür Karatekin, Karatekin, Claeys, Will Dunham, Rosalba O'Brien Organizations: Royal Observatory of, Vrije Universiteit Brussel, Nature, Dinos, Thomson Locations: North Dakota, WASHINGTON, Yucatan, Everest, Dakota, Royal Observatory of Belgium, Vrije, Belgium

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

☆ A condo on New York's Billionaires' Row sells for less than half of its original $135 million asking price
▼ + stars: | 2023-10-25 | by ( Pete Syme | ) www.businessinsider.com time to read: +2 min

A five-bedroom, five-bathroom unit at 432 Park Avenue was listed for $135 million back in 2021. Two years later, it's sold for less than half that to an anonymous buyer, The Real Deal reported. That same year, the 8,000-square-foot apartment on the 79th floor was put on the market for $135 million, according to The Real Deal. AdvertisementAdvertisementThis May, the asking price was lowered to $92 million, and the condo went into contract in August, per the real estate news outlet. The unit's listing agent, Noel Berk of Engel & Völkers, previously told The Real Deal that it was being marketed to Asian buyers.

Persons: it's, —, hasn't, Noel Berk, Engel, Völkers Organizations: Service, Real, The New York Times, Engineers, Deal, Times Locations: New York City, Russian, Greek

☆ AI, weight loss drugs and more: Portfolio manager names stocks to play 'new secular growth themes'
▼ + stars: | 2023-10-24 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

And then you overlay on top of that the emergence of two or three brand new secular growth themes," he said. CNBC Pro takes a look at the stocks he likes in three "brand new" areas of growth: obesity drugs, reshoring and artificial intelligence. Reshoring infrastructure Ayer sees bright spots in the reshoring theme too. The portfolio manager named tech giant Amazon as a good play of the AI wave. The way Ayer sees it, more companies in the U.S. are foraying into AI right now, compared to those in other parts of the world.

Persons: Sanjay Ayer, Ayer, He's bullish, —, Christina Cheddar Berk, Carmen Reinicke, Julie Coleman Organizations: CNBC Pro, WCM Investment Management, Equity Fund, Nordisk, Novo Nordisk, U.S . Food, Drug Administration, Tetra Tech, Canadian, Canadian Pacific, U.S Locations: U.S, China, Japan, India

☆ Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
▼ + stars: | 2023-10-23 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. Last month, the firm made a case for there being a $150 billion to $200 billion opportunity for these drugs. At the moment, private insurance coverage isn't a guarantee for those seeking weight loss treatment, and the federal Medicare program doesn't cover weight loss drugs at all. Lilly expects the Food and Drug Administration to approve this drug to treat obesity by the end of this year.

Persons: Seamus, Fernandez, Andrew Baum, Goldman Sachs, Chris Shibutani, Shibutani, Eli Lilly, Lilly Organizations: Monday, Citi, Wegovy, Food and Drug Administration Locations: GLP

☆ These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
▼ + stars: | 2023-10-22 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.

Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss

☆ GLP-1 weight loss drugs are creating opportunities for these 2 stocks, investment advisor says
▼ + stars: | 2023-10-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Developments surrounding the drugs, also popularly used for weight loss, have been disrupting anything from owners of dialysis centers to bariatric surgery providers and the food industry. But one investment advisor, Brian Krawez, president of Scharf Investments, says there are opportunities. "Many investors are concerned about the impacts of the GLP-1 drugs on a host of companies ranging from restaurants to consumer staples. Those mechanisms are the ones that help patients taking the drugs to lose weight and regulate their diabetes. They got roughly 35% market share, but a lot of people don't know the company," he said, adding that specialty pharmaceuticals — including the GLP-1 drugs —account for roughly 35% of the company's earnings.

Persons: Brian Krawez, Scharf, Mounjaro, Krawez, CNBC's, McKesson, It's, —, Christina Cheddar Berk, Julie Coleman Organizations: Scharf Investments, CNBC, Novo Nordisk, Walmart, Unilever, Unilever isn't Locations: GLP, U.S

☆ Ride the weight loss drug wave with this gym stock set to nearly double, says Evercore ISI
▼ + stars: | 2023-10-17 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Planet Fitness shares could soar as new weight loss drugs become popular and users flock to the gym, according to Evercore ISI. Shares of Planet Fitness have dropped about 30% in 2023, plunging 16% in a single day last month when the company announced the surprise ousting of CEO Chris Rondeau . Although GLP-1 drugs aid weight loss by suppressing appetite, it's still essential for patients to adopt healthy habits for long-term success. This is a positive development for Planet Fitness, resulting in a rush of new gym memberships, Cheng said. He estimated that one million new members would amount to roughly 15% upside in earnings per share for Planet Fitness by 2025.

Persons: Warren Cheng, Evercore, Chris Rondeau, Cheng, Citi's Peter Verdult, —, Christina Cheddar, Berk, Michael Bloom Organizations: Fitness, ISI, GLP, Planet Fitness, Planet

☆ Many are betting Ozempic will reduce the need for knee surgery. What it means if they're wrong
▼ + stars: | 2023-10-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. While the use of the GLP-1 drugs to treat obesity is still very limited at this point, it is expected to soar to a $100 billion market or more, by some estimates. Judging by the momentum in the stocks, investors have been betting that as people lose weight, there will be a decline in knee replacement surgery. A case for more knee surgery? Based on Truist's polling of 50 hospital administrators, the analyst expects the third quarter will show a slowing pace of knee replacement surgeries compared to the first half of 2023.

Persons: We've, Bill Sutherland, Piper Sandler, Matt O'Brien, Stryker, Eli Lilly's Mounjaro, O'Brien, Richard Newitter, Newitter, Benchmark's Sutherland, Kaiser, Sutherland, — CNBC's Michael Bloom Organizations: American College of, Nordisk's Ozempic, Stryker, Surgery Partners, Permanente, Tenet Healthcare, Partners Locations: U.S, GLP

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Bank of America sees risks for employers as insurance coverage of weight loss drugs grows
▼ + stars: | 2023-10-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

The eye-popping predictions for weight loss drug sales hinge on insurance companies agreeing to provide coverage of the pricey treatments, and momentum seems to be building on that front. The drugs include Novo Nordisk's semaglutide, which is sold as Ozempic for diabetes management and as Wegovy for weight loss. Unlike earlier generations of weight loss medicines, their side effects have been largely mild and included diarrhea, constipation and nausea. Higher hospital labor costs as well as GLP-1 medications are contributing to the biggest jump in health insurance costs since 2012, Lutz said. But those numbers will grow, especially as ongoing research continues to make the case for benefits beyond blood sugar control and weight loss.

Persons: Allen Lutz, Lutz, Lutz's, Savanta, Accolade, Eli Lilly, Mercer, Willis Towers Watson, Peter Verdult, Verdult, — CNBC's Michael Bloom Organizations: Bank of America, Accolade, Novo Nordisk's semaglutide, Food, Drug Administration, Citi, Nordisk, Centers for Disease Control Locations: U.S

☆ This animal health stock could gain nearly 30% as it ramps up sales of dog arthritis treatment
▼ + stars: | 2023-10-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

A recent survey conducted by Piper Sandler shows most of the 101 veterinarians it polled expect the prices they charge and the volume of patients they see to mostly hold up in the months ahead. While Piper Sandler "modestly" trimmed earnings estimates for 2024 for animal health-care companies Zoetis, Idexx Laboratories and Elanco Animal Health , Westenberg said Zoetis' products performed well in the survey. Solensia rang up $30 million in sales last year, but the opportunity for Librela is even bigger, according to the analyst. ZTS YTD mountain Even with the recent pullback in Zoetis stock, shares are up more than 18% year to date. In the Piper Sandler survey, few vets said they would pick the company's Credelio Quattro as their primary parasiticide when it is released.

Persons: Piper Sandler, David Westenberg, Westenberg, Librela, Solensia, Zoetis, FactSet, Quattro Organizations: Idexx Laboratories, U.S . Food, Drug Administration, Elanco Locations: parasiticides, U.S

☆ Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside
▼ + stars: | 2023-10-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +2 min

Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying the market is underpricing its odds for success heading into the release of clinical trial data. Admittedly, the upcoming trial results may not be successful, which makes the bet a risky one, he said. If Aclaris is successful with zunsemetinib, it will be the only MK2 inhibitor on the market for rheumatoid arthritis, which Evercore ISI sees as an advantage. A similar drug from Bristol Myers Squibb wasn't successful in a different form of arthritis. Evercore ISI expects investors are only pricing in a 20% chance of positive data from the clinical trial, whereas the firm expects the odds are closer to 50%.

Persons: Gavin Clark, Clark, Gartner, zunsemetinib, Aclaris, Bristol Myers Squibb wasn't, — CNBC's Michael Bloom Organizations: Evercore ISI, Aclaris Therapeutics, Gartner, Clark, Bristol Myers Squibb

☆ Stocks making the biggest moves midday: CarMax, Accenture, Peloton, Jefferies and more
▼ + stars: | 2023-09-28 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

DigitalBridge — Shares of the digital infrastructure company jumped 5.8% after JPMorgan upgraded the company to overweight from neutral. After the market closed Wednesday, Jefferies posted earnings of 22 cents per share on revenue of $1.18 billion. Accenture — Shares of the IT and consulting firm fell nearly 5% Thursday after Accenture reported mixed results for its fiscal fourth quarter. The used-car retailer's fiscal second-quarter earnings and revenue slipped from a year ago on weakening demand for used cars. Concentrix — Shares gained 10% a day after Concentrix said it would hike its quarterly dividend 10% to about 30 cents a share.

Persons: Trimble —, DigitalBridge, Jefferies, Duolingo, Wolfe, Lululemon, CarMax, Concentrix, FactSet, —, Jesse Pound, Christina Cheddar, Berk Organizations: Corporation, JPMorgan, Jefferies, UBS, Resorts, Wolfe Research, Accenture —, Accenture, StreetAccount, Micron, LSEG

☆ Will weight loss drugs lead to less food consumption? Here's what Walmart is saying
▼ + stars: | 2023-09-27 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

While there has been a huge gain, it is barely scratching the surface of the potential market. Some potential patients don't have coverage of the pricey medicines through their health insurance plans yet. (For example, those seeking to use GLP-1 drugs for obesity can't receive coverage if they are insured by Medicare as the federal health plan is not allowed to cover weight loss drugs.) Walmart told Bank of America that fiscal second-quarter sales benefited roughly 1% from GLP-1 drug sales volumes. Its stock has fallen 45% year to date on fears that these drugs will shrink the company's market potential.

Persons: John Rainey, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Wells, Larry Biegelsen, Biegelsen, Daniel Lyons, Janus Henderson, Lyons, — CNBC's Michael Bloom Organizations: Wall Street, Nordisk's Wegovy, Bank of, Walmart, Health, Novo Nordisk, Medicare, Drug, Bank of America, Janus, Janus Henderson Investors, CNBC Locations: U.S, GLP

☆ How the weight loss boom could impact the real estate market
▼ + stars: | 2023-09-26 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

NNN YTD mountain NNN REIT shares have fallen more than 22%. If that vision comes to pass, it could boost apartment operators such as Equity Residential , Avalonbay Communities and Apartment Income REIT , among others. PEAK YTD mountain Healthpeak shares are down 26% since January and hit a 52-week low Tuesday. Healthpeak shares hit a 52-week low on Tuesday, while Welltower shares shed more than 2%. Healthpeak shares are down more than 26% over the same period.

Persons: Jefferies, Jonathan Petersen, Petersen, Simon, Morgan Stanley, — CNBC's Michael Bloom Organizations: Federal Realty Investment Trust, Equity Locations: U.S, Canada

☆ Investors want to know when Philip Morris' smoke-free shift will pay off
▼ + stars: | 2023-09-26 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Anticipation should be building as Philip Morris prepares to bring iQOS back to the U.S. market. Philip Morris had partnered with Altria when iQOS was first launched in a handful of U.S. markets in 2019. Eventually, Philip Morris agreed to buy back the commercialization rights from Altria, and that deal is effective April 30, 2024. And this strategy is partly why, Herzog said, Philip Morris is one of Goldman's top picks. Last week, Philip Morris CEO Jacek Olczak spoke on X via ReutersPlus about its harm reduction efforts.

Persons: Philip, Goldman Sachs, Bonnie Herzog, Philip Morris, iQOS, Herzog, mgmt, Gaurav Jain, Jain, FactSet, Jacek Olczak, Jefferies, Owen Bennett, Bennett Organizations: Philip Morris International, Drug Administration, Altria, Barclays, Swedish Match, Bank of America, Rogue, Street Journal, Concordia, United Nations General Assembly Locations: U.S, Altria, New York

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Bet against America's love for junk food? Morgan Stanley sees tough times ahead for snack stocks like Hostess
▼ + stars: | 2023-09-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Smucker 's plan to buy Twinkies -maker Hostess Brands is a risky move, if Morgan Stanley's latest research is correct. The firm revisited its August call that a new class of weight loss medications would hamper growth at some food and beverage companies . "Across our coverage, Numerator Insights data highlight that most center-store packaged food companies slightly over-index to consumers with obesity," Kaufman said. Hostess stock soared 19% on the news. Other food stocks with higher exposure to customers with obesity include Conagra , Kraft Heinz and Smucker, the report said, citing the Numerator data.

Persons: Smucker, Morgan Stanley's, Ding Dongs, Morgan Stanley, Pamela Kaufman, Atkins, Nordisk's Wegovy, Kaufman, Kraft Heinz, — CNBC's Michael Bloom Organizations: Hostess Brands, Centers for Disease Control, Nordisk's Locations: U.S, GLP

☆ Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
▼ + stars: | 2023-09-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it. The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category. DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%. Dexcom shares are down more than 7% year to date. TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.

Persons: Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom Organizations: UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America Locations: CGMs

☆ 'Robot pills' could one day help patients avoid needles. The stocks are cheap, but risky
▼ + stars: | 2023-09-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

That's where a number of early-stage drug delivery companies come in — and most are flying under investors' radar. Drug delivery tends to be a "roll-up sector," explained Edward Nash, an analyst at Canaccord Genuity. Nash recently looked at four companies operating in drug delivery: Rani Therapeutics , Biora Therapeutics , Avalyn Pharma and Elektrofi. At the moment, the most effective GLP-1 medications for weight loss are delivered via a subcutaneous injection. The verstility of the Rani pill also is encouraging, according to Harrison, since it could be used with a wide range of drugs.

Persons: that's, Edward Nash, Nash, Rani, FactSet, Talat Imran, Eli Lilly, Evercore, Lilly, Genuity's Nash, Julian Harrison, Rani's, Harrison, Cantor Fitzgerald, Olivia Brayer, Imran, We're Organizations: Big Pharma, Therapeutics, Biora Therapeutics, Avalyn Pharma, CNBC, Novo Nordisk, Novo, European Union, Food and Drug Administration, Celltrion Locations: —

Search resuls for: "Berk"

25 mentions found